The current stock price of TTNP is 4.61 USD. In the past month the price increased by 9.76%. In the past year, price decreased by -13.02%.
ChartMill assigns a technical rating of 2 / 10 to TTNP. When comparing the yearly performance of all stocks, TTNP is a bad performer in the overall market: 69.92% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to TTNP. While TTNP seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months TTNP reported a non-GAAP Earnings per Share(EPS) of -5.23. The EPS increased by 29.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -161% | ||
| ROE | -192.87% | ||
| Debt/Equity | 0 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.54 | 969.015B | ||
| JNJ | JOHNSON & JOHNSON | 20.46 | 574.257B | ||
| MRK | MERCK & CO. INC. | 21.65 | 290.769B | ||
| PFE | PFIZER INC | 9.19 | 156.982B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10 | 123.896B | ||
| ZTS | ZOETIS INC | 18.66 | 56.466B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.52 | 25.52B | ||
| VTRS | VIATRIS INC | 6.31 | 18.371B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.5 | 12.725B | ||
| AXSM | AXSOME THERAPEUTICS INC | 225.04 | 9.291B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. The company is headquartered in San Francisco, California. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus, and Nalmefene Implant, which is for the prevention of relapse in OUD patients following detoxification from opioids Its product development programs are in non-clinical stages of development.
TITAN PHARMACEUTICALS INC
Suite 505, 400 Oyster Point Blvd
San Francisco CALIFORNIA 94080 US
CEO: Marc Rubin
Employees: 4
Phone: 14152444990
Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. The company is headquartered in San Francisco, California. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus, and Nalmefene Implant, which is for the prevention of relapse in OUD patients following detoxification from opioids Its product development programs are in non-clinical stages of development.
The current stock price of TTNP is 4.61 USD. The price decreased by -3.76% in the last trading session.
TTNP does not pay a dividend.
TTNP has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
TITAN PHARMACEUTICALS INC (TTNP) operates in the Health Care sector and the Pharmaceuticals industry.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TTNP.
TITAN PHARMACEUTICALS INC (TTNP) will report earnings on 2026-01-01.